BRIEF published on 02/20/2026 at 21:42, 12 days 21 hours ago Teva's Olanzapine Injectable Suspension Gains FDA Nod Schizophrenia Olanzapine Teva Pharmaceuticals FDA Acceptance Long-acting Injectable
PRESS RELEASE published on 02/20/2026 at 21:37, 12 days 21 hours ago Inside Information / Other news releases FDA accepts Teva's NDA for once-monthly olanzapine for schizophrenia treatment, addressing treatment gap. Teva and Medincell collaborate for innovative solution FDA Schizophrenia Medincell Olanzapine Teva
BRIEF published on 02/19/2026 at 10:33, 14 days 8 hours ago Mirova crosses a threshold at MEDINCELL Euronext Paris Voting Rights Transfer Of Shares Mirova MEDICELL
BRIEF published on 12/09/2025 at 14:55, 2 months 27 days ago Teva Pharmaceuticals submits an application for authorization for Olanzapine LAI FDA Schizophrenia Medincell Teva Pharmaceuticals Olanzapine LAI
BRIEF published on 12/09/2025 at 14:55, 2 months 27 days ago Medincell and Teva Submit FDA Application for New Injectable Treatment Schizophrenia Treatment Medincell FDA Submission Teva Pharmaceuticals Olanzapine LAI
PRESS RELEASE published on 12/09/2025 at 14:50, 2 months 27 days ago Inside Information / Other news releases Teva Pharmaceuticals submits NDA to FDA for Olanzapine Extended-Release Injectable Suspension (TEV-'749 / mdc-TJK) for Once-Monthly Schizophrenia Treatment. Medincell focuses on long-acting injectable treatments across therapeutic areas Schizophrenia Medincell Olanzapine NDA Teva Pharmaceuticals
BRIEF published on 11/11/2025 at 08:05, 3 months 24 days ago Medincell Expands Dr Grace Kim's Role to Boost US Capital Growth Biotechnology Medincell Pharmaceutical Strategy Dr Grace Kim US Capital Growth
PRESS RELEASE published on 11/11/2025 at 08:00, 3 months 24 days ago Inside Information / Other news releases Medincell appoints Dr. Grace Kim as Chief Strategy Officer, U.S. Finance to lead U.S. capital growth strategy. Medincell pioneers long-acting injectable therapies Medincell Dr. Grace Kim Long-acting Injectable Therapies U.S. Capital Growth Clinical-stage Pharmaceutical Company
BRIEF published on 11/05/2025 at 13:51, 4 months ago Continued growth for Medincell and new prospects with Olanzapine LAI Schizophrenia Medincell Teva Pharmaceuticals Olanzapine LAI UZEDY
PRESS RELEASE published on 11/05/2025 at 13:46, 4 months ago Inside Information / Other news releases Medincell's partner Teva plans US NDA submission for Olanzapine LAI in Q4 2025, while UZEDY® achieves continued growth in sales in Q3 2025 Medincell Teva Pharmaceuticals Olanzapine LAI US NDA Submission UZEDY Sales Growth
Published on 03/05/2026 at 17:55, 1 hour 10 minutes ago ACCESS Newswire to Host Fourth Quarter and Year End Earnings Conference Call on March 19, 2026
Published on 03/05/2026 at 14:00, 5 hours 5 minutes ago EQ Inc. Secures Strategic Partnership with Global Card Network to Expand Integrated Rewards Across Canada
Published on 03/05/2026 at 14:00, 5 hours 5 minutes ago GameSquare's Stream Hatchet Publishes 2025 YouTube Gaming Trends Report
Published on 03/05/2026 at 14:00, 5 hours 5 minutes ago Horizon Aircraft's Unique VTOL Delivers Up to 75% Lower Operating Costs Than Helicopters
Published on 03/05/2026 at 13:40, 5 hours 25 minutes ago Lobe Sciences Ltd. Announces Presence in Miami During the Jefferies and Leerink Healthcare Conferences
Published on 03/05/2026 at 17:57, 1 hour 8 minutes ago EQS-Adhoc: Delivery Hero SE may redeem convertible bonds in H1 2026 using proceeds from a USD 1.5bn increase of its term loans subject to certain conditions
Published on 03/05/2026 at 17:48, 1 hour 16 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 03/05/2026 at 17:45, 1 hour 19 minutes ago Swiss Prime Site announces the conversion price of its CHF 350 million green convertible bonds due 2032 and the outcome of the incentivized conversion invitation
Published on 03/05/2026 at 18:40, 25 minutes ago 2025 Full-year results FREY: a pan-European platform already creating value
Published on 03/05/2026 at 18:34, 30 minutes ago Mersen: Number of shares and voting rights as of February 28, 2026
